Premium
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab
Author(s) -
Kelly Richard,
Arnold Louise,
Richards Stephen,
Hill Anita,
Bomken Charlotte,
Hanley John,
Loughney Andrew,
Beauchamp Jon,
Khursigara Gus,
Rother Russell P.,
Chalmers Elizabeth,
Fyfe Andrew,
Fitzsimons Edward,
Nakamura Ryotaro,
Gaya Anna,
Risitano Antonio M.,
Schubert Jörg,
Norfolk Derek,
Simpson Nigel,
Hillmen Peter
Publication year - 2010
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08099.x
Subject(s) - eculizumab , medicine , pregnancy , pediatrics , obstetrics , complement system , immunology , antibody , biology , genetics
Summary In Paroxysmal nocturnal haemoglobinuria (PNH), pregnancy is associated with increased maternal and foetal complications to such an extent that the condition has been considered relatively contra‐indicated in PNH. Eculizumab has revolutionized the treatment of PNH. We evaluate its use in pregnancy to date. We report on seven patients exposed to eculizumab at different stages of pregnancy including the first two patients to receive the drug from conception to delivery. There was no evidence of complement blockade from cord blood samples taken at delivery. Eculizumab appears safe to use in this setting and is likely to prevent many of the complications usually observed.